APA (7th ed.) Citation

Sharma, E., Allah-Ditta, M., Povlsen, S., Greenwood, J., Shinh, S., Omrani, F., . . . Kirkbride, M. (2026). Switching from ustekinumab originator to biosimilar: No adverse impact on inflammatory bowel disease control and well tolerated by patients in a UK multicentre study. Journal of Crohn's & Colitis, 20, i2723.

Chicago Style (17th ed.) Citation

Sharma, E., et al. "Switching from Ustekinumab Originator to Biosimilar: No Adverse Impact on Inflammatory Bowel Disease Control and Well Tolerated by Patients in a UK Multicentre Study." Journal of Crohn's & Colitis 20 (2026): i2723.

MLA (9th ed.) Citation

Sharma, E., et al. "Switching from Ustekinumab Originator to Biosimilar: No Adverse Impact on Inflammatory Bowel Disease Control and Well Tolerated by Patients in a UK Multicentre Study." Journal of Crohn's & Colitis, vol. 20, 2026, p. i2723.